Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants: A Randomized Controlled Trial (The PRELUDE Trial)
Status: Recruiting
Location: See location...
Intervention Type: Other, Dietary supplement
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5 months
Maximum Age: 6 months
Healthy Volunteers: f
View:
• Infants born at Papageorgiou Hospital in Neonatology Department and NICU of Aristotle University of Thessaloniki with GA equal to or less than 29 weeks are eligible to participate in the study.
Locations
Other Locations
Greece
Papageorgiou General Hospital
RECRUITING
Thessaloniki
Contact Information
Primary
Maria Lithoxopoulou, MD, PhD, MBA, Ass. Prof.
mlithoxopoulou@yahoo.com, lithoxopoulou@auth.gr
+30 6932883161
Time Frame
Start Date: 2025-03-04
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 74
Treatments
Experimental: Enteral supplementation
Enteral supplementation with ARA and DHA (in a 2:1 ratio) in addition to standard care and feeding.
Active_comparator: Routine practice
Routine clinical care and nutritional support
Related Therapeutic Areas
Sponsors
Leads: Aristotle University Of Thessaloniki